Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
They died 'doing what they loved': The stories of workers in their 80s who died on the job - 2This Luxurious Thermal Spa In Italy Is Perfect For A Relaxing Escape While Visiting Milan
- 3More than 3 million eye drops have been recalled from CVS, Walgreens and other national retailers. How to check if yours are safe
- 4The Most Compelling Books of the 10 years
- 5One perk to marrying Richard Marx later in life? 'We don't have time' for stupid arguments, says Daisy Fuentes.
- Launch pad damaged as Russian rocket blasts off for space station, agency says
- Israel reports first missile fire from Yemen since start of Iran war
- Exploring the Gig Economy: Examples from Consultants
- Humpback whale freed by rescuers in Baltic Sea has become stranded again
- Flu cases skyrocket in US. See cases, where people got sick.
- Robert Pattinson claims he's a pathological liar. What 'The Drama' star has said about his 'shtick'
- UK, Canada, Germany, others condemn Israel's West Bank settlement plan
- Equality requires universal draft, participation in economy and workforce, MK Liberman says
- Countdown to Artemis II: What to know about NASA's moon mission
